Nachrichten zur Gilead Sciences Inc. Aktie

This Company Just Initiated a Quarterly Dividend: Time to Buy?

Biotech giant Renegeron Pharmaceuticals (NASDAQ: REGN) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The companys results were…

Gilead Sciences, Inc. (GILD) Hit a 52 Week High, Can the Run Continue?

Gilead (GILD) is at a 52-week high, but can investors hope for more gains in the future? We take a…

Why Gilead Sciences Stock Is Jumping Today

Shares of Gilead Sciences (NASDAQ: GILD) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after…

Gilead Sciences Aktie: Biotech-Riese steigert Dividende

Kulmbach (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Gilead Sciences (GILD) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Heres why…

Gilead: Starke Zahlen, höhere Dividende – Aktie startet durch

Der amerikanische Biotech-Riese Gilead Sciences hat im Schlussviertel 2024 überraschend stark abgeschnitten. Sowohl Umsatz als auch Ergebnis je Aktie lagen…

Gilead Sciences Aktie: HIV-Geschäft stabil - Wachstum durch neue Produkte

San Francisco (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Wells Fargo Advisors: Rating und Kursziel Wells Fargo-Analyst Mohit Bansal hat das Kursziel für die…

Gilead Sciences: Strong Q4 Results And Huge Progress In HIV

…

Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript

GILD earnings call for the period ending December 31, 2024.…

Gilead Sciences, Inc. 2024 Q4 - Results - Earnings Call Presentation

…

Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript

…

GILD Stock Up on Q4 Earnings and Sales Beat & Upbeat 25 Guidance

Gilead Sciences Q4 earnings and sales beat estimates on higher HIV, oncology and liver disease drug sales. The stock is…

Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates

Gilead (GILD) delivered earnings and revenue surprises of 13.77% and 7.27%, respectively, for the quarter ended December 2024. Do the…

Gilead Sciences Beats Q4 EPS Forecast

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.…

Gilead quarterly results beat estimates

Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% and…

Gilead Sciences Q4 Earnings Preview: Slight fall in profit expected

…

The Zacks Analyst Blog Uber, Comcast, Gilead Sciences and Onfolio Holdings

Uber, Comcast, Gilead Sciences and Onfolio Holdings are included in this Analyst Blog.…

Gilead Sciences Aktie: 115 oder 83 USD? Kursziele und Ratings der Analysten vor Q4-Zahlen auf einen Blick - Aktiennews

Foster City (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen…

3 Fabulous Dividend Stocks to Buy in February

February is the shortest month, but that doesnt mean income investors dont have much time to find great stocks. Three…

These 2 Dividend Stocks Are Absolute Bargains Right Now

Dividend stocks are great for many reasons, not least because any company that can sustain growing payouts for a long…

Top Analyst Reports for Uber, Comcast & Gilead

Todays Research Daily features new research reports on 16 major stocks, including Uber Technologies, Inc. (UBER), Comcast Corporation (CMCSA) and…

3 Top AI-Powered Biotech Stocks to Buy in February

Artificial intelligence (AI) is transforming various industries as a major investing theme in 2025. The technologys ability to automate complex…

Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing

Gilead Sciences (GILD) closed at $99.65 in the latest trading session, marking a +1.69% move from the prior day.…

Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…

Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts

In the most recent trading session, Gilead Sciences (GILD) closed at $98.38, indicating a +1.21% shift from the previous trading…

8 Health Care Stocks Whale Activity In Todays Session - Hims & Hers Health (NYSE:HIMS), Gilead Sciences (NASDAQ:GILD)

…

Top Stock Reports for Salesforce, Shell, Gilead Sciences & Others

Todays Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc (SHEL) and Gilead…

Gilead Sciences, US government settle patent case over HIV prevention drugs

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gileads HIV prevention drugs Truvada and Descovy,…

Gilead Sciences, US government settle patent case over HIV prevention drugs By Reuters

Gilead Sciences, US government settle patent case over HIV prevention drugs…

Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript)

…

Gilead, LEO Pharma partner to develop programs for inflammatory diseases

Gilead Sciences said on Saturday that it entered into a partnership with Denmarks LEO Pharma to develop programs to treat…

Gilead backs proposed Poolbeg Pharmas proposed tie-up with HOOKIPA

Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS), the largest shareholder in HOOKIPA Pharma, has thrown its backing behind the proposed merger with…

Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise

…

Heres How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address unmet medical needs in the United…

Gilead Sciences Aktie: Partner Arcellx veröffentlicht positive klinische Ergebnisse

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Oppenheimer: Aktuelle Bewertung Oppenheimer hat das Kursziel für die Aktie von Gilead Sciences Inc. (ISIN:…

Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences

Todays Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), AbbVie Inc. (ABBV)…

Gilead Sciences, Inc. (GILD) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)

…

Gilead Sciences, Inc. (GILD) Piper Sandler 36th Annual Healthcare Conference (Transcript)

…

Studie: Gilead-Wirkstoff schützt effektiv vor HIV-Infektion

FOSTER CITY (dpa-AFX) - Eine halbjährliche Impfung mit dem Medikament Lenacapavir schützt effektiv vor einer Infektion…

Gilead Sciences Aktie: Potenzial im HIV-Geschäft - UBS sieht Wachstumschancen und hebt Kursziel an

Zürich (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von der UBS: Aktuelle Bewertung UBS hat das Kursziel für Gilead Sciences Inc. (ISIN: US3755581036, WKN: 885823,…

Gilead Sciences: Kursziel angehoben

New York (www.aktiencheck.de) - Rating-Update: Die Analysten von Mizuho Securities USA stufen die Aktie von Gilead Sciences Inc. (ISIN: US3755581036, WKN:…

Gilead Sciences Aktie: 125 oder 84 USD? Kursziele und Ratings der Analysten nach Q3-Zahlen auf einen Blick - Aktiennews

Bad Marienberg (www.aktiencheck.de) - Welche Kursziele und Ratings trauen die Analysten der führenden Banken und Research-Häuser der Aktie des biopharmazeutischen…

Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)

…

Gilead Sciences Aktie: Attraktive Perspektiven dank FDA-Zulassung und starker Pipeline

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Argus Research: Rating und Kursziel Argus hat das Kursziel für die Aktien von Gilead Sciences…

Gilead Sciences Aktie: Kursziel leicht angehoben, aber Unsicherheiten bleiben

Toronto (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von RBC Capital Markets: Aktuelle Bewertung Brian Abrahams von RBC Capital hat das Kursziel für Gilead Sciences…

Gilead Sciences Aktie: Signifikantes Aufwärtspotenzial

New York (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Wolfe Research: 1. Zusammenfassung der Bewertung Wolfe Research bewertet die Aktie von Gilead Sciences Inc.…

Gilead Sciences: Approaching Overvalued

…

Gilead Sciences Aktie: Bewertung erreicht 5-Jahres-Hoch - Herabstufung!

New York (www.aktiencheck.de) - Gilead Sciences Aktie: Aktienanalyse von Maxim Group: Rating und Kursziel Maxim hat das Rating für die Aktie von…

Gilead Sciences Aktie: Solides Q3-Ergebnis und optimistischer Ausblick - Starkes Wachstum im HIV-Bereich

St. Petersburg (www.aktiencheck.de) - Gilead Sciences-Aktienanalyse von Raymond James: Aktuelle Bewertung Raymond James hat das Kursziel für Gilead Sciences Inc. (ISIN: US3755581036,…

Gilead Sciences: Kursziel angehoben

Milwaukee (www.aktiencheck.de) - Rating-Update: Die Analysten von Robert W. Baird stufen die Aktie von Gilead Sciences Inc. (ISIN: US3755581036, WKN: 885823,…